Wesper Journal

OSA and GLP-1's

In a landmark move, the FDA approved Zepbound (tirzepatide), the first GLP-1-based medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, offering hope beyond traditional CPAP therapy. It works by activating GLP-1 and GIP hormone...

BMI and Sleep Apnea: Evaluating the Role of Weight, Aging, and Gender in OSA Severity and Hypoxic Burden

This article explores the relationship between BMI, age, and gender in obstructive sleep apnea (OSA) severity and hypoxic burden. Analyzing two patient cohorts, the study finds that higher BMI is linked to increased apnea-hypopnea index (AHI) and hypoxic burden, though its effect plateaus in severe obesity. Age and male gender emerge as stronger predictors of OSA severity in obese individuals. The findings highlight the potential of GLP-1-induced weight loss to reduce OSA severity but emphasize the need for a multimodal approach, integrating weight management with traditional OSA treatments like CPAP for optimal patient outcomes.

our research

The Wesper Journal is our weekly publication dedicated to exploring sleep apnea, sleep health, and the latest updates from Wesper. Each edition offers expert insights, practical tips, and valuable resources to help you better understand and improve your sleep, empowering you to take control of your sleep health journey.